Opportunity 路 OpportunityJun 19, 2026 路 17:45 CET
Roche posts positive Phase III for Parkinson's drug
Roche reported a successful Phase III readout on its lead Parkinson's asset. CIO upgraded Roche to Buy. Strong narrative fit for the Schneider family foundation and for Karin Stadler's biotech-focused mandate.
3 of 3 selected
Hubertus & Carmen Schneider
UHNWI 路 Zug, CH 路 CET
Fit score98/100
Suggested ticketCHF 0.58M
Direct alignment with the family's neurology mission.
Channel Phone
StyleValues-driven
Draft, tailored to client DNA
Sends via Phone at next sensible window for CET.
Karin Stadler
HNWI 路 Bern, CH 路 CET
Fit score91/100
Suggested ticketCHF 0.40M
Adds conviction to her biotech overweight.
Channel Email
StyleNumbers-first
Draft, tailored to client DNA
Sends via Email at next sensible window for CET.
Dr. Beatrice Merian
UHNWI 路 Basel, CH 路 CET
Fit score76/100
Suggested ticketCHF 0.30M
ESG-clean Swiss healthcare anchor.
Channel Phone
StyleValues-driven
Draft, tailored to client DNA
Sends via Phone at next sensible window for CET.
Every message requires RM approval before send. No automated trades are placed from this screen.